Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Down Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape. Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and ... Read More
-
Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no ... Read More
-
Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline landscape. Venous leg ulcers develop when persistently ... Read More
-
Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and ... Read More
-
Atopic Dermatitis - Epidemiology Analysis and Forecast, 2020-2030
... primarily common among infants and children (Bowcock and Cookson, 2004). In general, the prevalence of AD is increasing worldwide, with high prevalence in Western and developed nations compared with other parts of the world. However, ... Read More
-
Global Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Regional Outlook and Forecast, 2021 - 2027
... Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period. Benign prostatic hyperplasia (BPH) is a benign swelling of ... Read More
-
Europe Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021 - 2027
... Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 3.9% CAGR during the forecast period (2021-2027). BPH is neither a malignancy nor a cause of prostate cancer. BPH, on the other hand, can be ... Read More
-
Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape. Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the ... Read More
-
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The ... Read More
-
Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape. Hyperalgesia is an increase in pain response. Predisposing factors include long term opioid usage, inflammation, damage ... Read More
-
Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape. Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements ... Read More
-
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... recently published report 'Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Hepcidin ... Read More
-
Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator ... Read More
-
North America Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021 - 2027
... North America Benign Prostatic Hyperplasia Therapeutics Market would witness market growth of 3.4% CAGR during the forecast period (2021-2027). The condition in which the prostate and surrounding tissue enlarge, it is known as benign prostatic ... Read More
-
Intermittent Claudication Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Intermittent Claudication (Cardiovascular) pipeline landscape. Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood ... Read More
-
Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is ... Read More
-
Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape. Nasopharyngitis also known as common cold is an infectious, ... Read More
-
Nocturia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape. Nocturia is defined as need to urinate at least twice during the night. ... Read More
-
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Summary According to the recently published report 'Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, ... Read More
-
Transcriptomics Market by Type (Consumables, Instruments, Software, and Services), Technology (Microarrays, Qpcr, and Sequencing Technology), Application (Drug Discovery, Diagnostics & Disease Profiling, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030
... valued at $5,790.51 million in 2020, and is estimated to reach $11,397.08million by 2030, growing at a CAGR of 7.0% from 2021 to 2030.Transcriptomics is the collection and study of RNA present in different types ... Read More
-
Hematological Malignancies Emerging Therapeutics Market - A Global and Regional Analysis: Focus on Therapeutic Type (Marketed), Potential Pipeline Products, Indication, and Region - Analysis and Forecast, 2021-2031
... Market Segmentation Marketed Drugs - Monoclonal Antibodies and CAR-T Cell Therapy Potential Pipeline Products - Monoclonal Antibodies and CAR-T Cell Therapy Indication - Leukemia, Lymphoma, and Multiple Myeloma Regional Segmentation North America - U.S. and ... Read More
-
Digital Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application [Diabetes, Cardiovascular Diseases, Central Nervous System (CNS) Diseases, Respiratory Diseases, Smoking Cessation, Musculoskeletal Diseases, and Other Applications] and Distribution Channel (Patients, Providers, Payers, and Employers)
... Providers, Payers, and Employers) The global digital therapeutics market is expected to grow from US$ 4,226.94 million in 2021 to US$ 18,061.79 million by 2028; it is estimated to grow at a CAGR of 23.1% ... Read More
-
Blood Based Biomarker Market, By Type (Screening Biomarker, Diagnosis Biomarker, and Others), By Disease (Cancer, Neurological Disorders, and Others), By Application (Diagnostics, Drug Discovery, and Personalized Medicine), and By Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
... Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 The term biomarker, or biological marker, refers to a broad range of measures that capture what is happening in a ... Read More
-
Global Antisynthetase Syndrome Market Size study, by Symptoms (Muscle Disease, Interstitial Lung Disease, Arthritis) by Gender (Male, Female) by Diagnosis (Clinical Testing, Workup) by Treatment (Medication, Physical Therapy) and Regional Forecasts 2022-2028
... Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Antisynthetase Syndrome is a type of ... Read More
-
Indian Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, And Segment Forecasts, 2022 - 2030
... to expand at a CAGR of 8.2% from 2022 to 2030. The globalization of clinical trials, growing disease variation and prevalence in the country, adoption of new technology in clinical research, and increasing R&D promoting ... Read More
Research Assistance
